Captor Therapeutics S.A. (WAR:CTX) — Stock Price
Captor Therapeutics S.A. (WAR:CTX) is currently trading at zł69.90 PLN, down 0.14% today. Over the past 52 weeks, shares have ranged between zł34.60 and zł87.60. This page tracks Captor Therapeutics S.A.'s live share price on the WAR exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Captor Therapeutics S.A. (CTX) market capitalisation.
Captor Therapeutics S.A. (CTX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Captor Therapeutics S.A.'s daily closing share price and trading volume on the WAR exchange over the past year, giving a clear view of recent price momentum and liquidity.
Captor Therapeutics S.A. Income Statement — Revenue, Profit & Earnings by Year
Captor Therapeutics S.A.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | zł15.82 Million | zł13.20 Million | zł9.16 Million | zł3.99 Million | zł1.45 Million |
| Cost of Revenue | zł9.40 Million | zł6.30 Million | zł2.09 Million | zł741.00K | zł6.60 Million |
| Gross Profit | zł6.42 Million | zł6.90 Million | zł7.07 Million | zł3.25 Million | zł-6.60 Million |
| Research & Development | zł34.66 Million | zł64.85 Million | zł44.16 Million | zł23.11 Million | zł23.57 Million |
| SG&A | zł4.13 Million | zł16.14 Million | zł19.56 Million | zł19.55 Million | zł4.20 Million |
| Total Operating Expenses | zł51.18 Million | zł79.92 Million | zł45.44 Million | zł34.95 Million | zł26.85 Million |
| Operating Income | zł-44.76 Million | zł-73.02 Million | zł-38.36 Million | zł-31.71 Million | zł-12.22 Million |
| EBITDA | zł-32.93 Million | zł-64.76 Million | zł-28.22 Million | zł-24.41 Million | zł-5.70 Million |
| EBIT | zł-37.99 Million | zł-70.20 Million | zł-35.31 Million | zł-31.77 Million | zł-12.30 Million |
| Interest Expense | zł437.00K | zł323.00K | zł579.00K | zł400.00K | zł393.00K |
| Income Before Tax | zł-38.43 Million | zł-70.53 Million | zł-35.89 Million | zł-32.57 Million | zł-12.69 Million |
| Income Tax Expense | — | zł57.00K | — | — | — |
| Net Income | zł-38.43 Million | zł-70.58 Million | zł-35.89 Million | zł-32.57 Million | zł-13.09 Million |
Captor Therapeutics S.A. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Captor Therapeutics S.A.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | zł87.50 Million | zł97.29 Million | zł113.00 Million | zł143.54 Million | zł25.78 Million |
| Total Current Assets | zł78.09 Million | zł88.65 Million | zł101.32 Million | zł130.56 Million | zł13.25 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | zł19.85 Million | — | — |
| Net Receivables | zł38.25 Million | zł12.57 Million | zł9.68 Million | zł11.71 Million | zł2.59 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | zł12.61 Million | zł12.20 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | zł23.02 Million | zł28.07 Million | zł16.68 Million | zł19.34 Million | zł26.78 Million |
| Total Current Liabilities | zł20.03 Million | zł26.73 Million | zł13.39 Million | zł16.37 Million | zł20.01 Million |
| Long-term Debt | zł0.00 | zł0.00 | zł0.00 | zł0.00 | zł214.00K |
| Net Debt | zł-33.62 Million | zł-71.93 Million | zł-64.08 Million | zł-109.76 Million | zł1.79 Million |
| Total Stockholder Equity | zł64.47 Million | zł69.22 Million | zł96.32 Million | zł124.20 Million | zł-1.00 Million |
| Retained Earnings | zł-203.11 Million | zł-164.69 Million | zł-94.10 Million | zł-58.21 Million | zł-25.64 Million |
Captor Therapeutics S.A. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Captor Therapeutics S.A. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | zł-31.88 Million | zł-52.20 Million | zł-22.95 Million | zł-28.47 Million | zł-595.00K |
| Capital Expenditures | zł424.00K | zł3.00 Million | zł892.00K | zł5.11 Million | zł212.00K |
| Free Cash Flow | zł-32.06 Million | zł-55.21 Million | zł-23.84 Million | zł-33.59 Million | zł-807.00K |
| Investing Cash Flow | zł273.00K | zł19.93 Million | zł-17.63 Million | zł-5.11 Million | zł-212.00K |
| Financing Cash Flow | zł-4.84 Million | zł36.94 Million | zł-6.33 Million | zł140.88 Million | zł-881.00K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | zł1.99 Million | zł4.58 Million | zł8.01 Million | zł9.49 Million | zł1.73 Million |
| Depreciation | zł5.06 Million | zł5.44 Million | zł7.09 Million | zł7.36 Million | zł6.60 Million |
| Change in Cash | zł-36.45 Million | zł4.67 Million | zł-46.91 Million | zł107.29 Million | zł-1.69 Million |
Captor Therapeutics S.A. Earnings History — EPS Actual vs. Analyst Estimates
Track Captor Therapeutics S.A.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 21, 2025 | -2.08 | — | — |
| Sep 11, 2025 | -1.78 | — | — |
| Apr 15, 2025 | -1.59 | — | — |
| Nov 08, 2024 | -2.20 | — | — |
| Sep 05, 2024 | -2.14 | — | — |
| May 29, 2024 | -2.47 | — | — |
| Nov 28, 2023 | -3.72 | — | — |
| Sep 07, 2023 | -6.91 | — | — |